{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:12:27Z","timestamp":1793913147977,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109638","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:13:47Z","timestamp":1790687627000},"page":"109638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Systemic and intracranial activity of antibody\u2013drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5653-999X","authenticated-orcid":false,"given":"Susu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5938-7471","authenticated-orcid":false,"given":"Jiayi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishw","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5007-8808","authenticated-orcid":false,"given":"Noriko","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Homsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Kai","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2026.109638_b0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: management of non\u2011small-cell lung cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"key":"10.1016\/j.lungcan.2026.109638_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102807","article-title":"Central nervous system metastases in advanced non-small cell lung cancer: a review of the therapeutic landscape","volume":"130","author":"Weller","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109638_b0015","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.21037\/tcr-2025-1434","article-title":"An updated review on systemic therapy for brain metastases in non-small cell lung cancer","volume":"14","author":"Louis","year":"2025","journal-title":"Transl. Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109638_b0020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109638_b0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.21037\/tlcr.2016.10.16","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future","volume":"5","author":"Proto","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109638_b0030","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.3390\/cells10102620","article-title":"Research progress and challenges in the treatment of central nervous system metastasis of non-small cell lung cancer","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109638_b0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"31","key":"10.1016\/j.lungcan.2026.109638_b0040","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.lungcan.2026.109638_b0045","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109638_b0050","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2026.109638_b0055","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109638_b0060","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1556-0864(25)00208-4","article-title":"13P: Brain metastases and actionable genetic alterations with sacituzumab govitecan versus docetaxel in metastatic non-small cell lung cancer: subgroups of the phase III EVOKE-01 trial","volume":"20","author":"Felip","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109638_b0065","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","article-title":"Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours","volume":"20","author":"Mair","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109638_b0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11060-025-05083-0","article-title":"Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges","volume":"174","author":"Robert","year":"2025","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.lungcan.2026.109638_b0075","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109638_b0080","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109638_b0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11523-025-01188-8","article-title":"Can PARP inhibitors benefit patients with homologous recombination repair-proficient castration-resistant prostate cancer? A meta-analysis","volume":"21","author":"Zhou","year":"2026","journal-title":"Target Oncol."},{"key":"10.1016\/j.lungcan.2026.109638_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1750743X.2026.2722581","article-title":"Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysis","volume":"25","author":"Zhou","year":"2026","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109638_b0095","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109638_b0100","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jtho.2025.07.129","article-title":"Final Analysis results and patient-reported outcomes from DESTINY-Lung02-a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC","volume":"20","author":"J\u00e4nne","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109638_b0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.43107","article-title":"Trastuzumab deruxtecan for ERBB2-mutant metastatic non-small cell lung cancer with or without brain metastases: a secondary analysis of randomized clinical trials","volume":"8","author":"J\u00e4nne","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109638_b0110","article-title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant (HER2m) non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases (mets): results from DESTINY-Lung05 (DL-05)","volume":"44","author":"Li","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109638_b0115","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","article-title":"Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109638_b0120","doi-asserted-by":"crossref","first-page":"8593","DOI":"10.1200\/JCO.2024.42.16_suppl.8593","article-title":"Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced\/metastatic non-small cell lung cancer (a\/m NSCLC) with actionable genomic alterations (AGA): results from TROPION-Lung05","volume":"42","author":"Lisberg","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109638_b0125","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(25)00465-6","article-title":"Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Fuereder","year":"2025","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109638_b0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.annonc.2024.02.003","article-title":"Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC","volume":"35","author":"Yu","year":"2024","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109638_b0135","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109638_b0140","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jtho.2025.09.061","article-title":"OA10.01 intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with advanced\/metastatic NSCLC in TROPION-Lung01","volume":"20","author":"Pons-Tostivint","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109638_b0145","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2025.43.16_suppl.8506","article-title":"Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study","volume":"43","author":"Mok","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109638_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103651","article-title":"Systemic and Intracranial efficacy and safety of trastuzumab deruxtecan in patients with HER2-mutant NSCLC across treatment lines: evidence from the TRACER\/HERTras real-world cohort","volume":"21","author":"Illini","year":"2026","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109638_b0155","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.21037\/tlcr-2025-916","article-title":"Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with HER2-mutant metastatic non-small cell lung cancer: a retrospective study","volume":"14","author":"Huang","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109638_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103083","article-title":"Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: what have we accomplished so far?","volume":"143","author":"Cheo","year":"2026","journal-title":"Cancer Treat. Rev."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109638_b0165","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.21037\/tlcr-24-964","article-title":"The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review","volume":"13","author":"Zhou","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109638_b0170","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11912-025-01655-5","article-title":"Targeting lung cancer with precision: the ADC therapeutic revolution","volume":"27","author":"Tawfiq","year":"2025","journal-title":"Curr. Oncol. Rep."},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2026.109638_b0175","article-title":"Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: where are we and where are we going?","volume":"132","author":"Parisi","year":"2026","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.lungcan.2026.109638_b0180","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:08:08Z","timestamp":1792037288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":36,"alternative-id":["S0169500226006999"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109638","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic and intracranial activity of antibody\u2013drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109638"}}